Q1 miss not a worry; expect another boost for the share price
07/05/24 -"Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main growth driver this Q1 in contrast with a weak quarter ..."
Pages
53
Language
English
Published on
07/05/24
You may also be interested by these reports :
17/05/24
We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of ...
15/05/24
The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless ...
15/05/24
Merck started the year well, with Electronics being the largest contributor, demonstrating organic sales growth after several stagnant quarters. ...
15/05/24
The Q1 results largely met the consensus, as the firm’s key blood-plasma-derived proteins witnessed strong demand, profitability continued to expand ...